(Q38331244)

2 September 2017

1 reference

title

Biosimilars: clinical interpretation and implications for drug development (English)

1 reference

2 September 2017

Eduardo Mysler

1

1 reference

2 September 2017

publication date

1 February 2015

1 reference

Current Rheumatology Reports

2 September 2017

published in

1 reference

2 September 2017

volume

17

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

8

1 reference

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

Non-inferiority trials: the 'at least as good as' criterion with dichotomous data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

The role of biosimilars in the treatment of rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

Immunogenicity of therapeutic proteins: clinical implications and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

Generics and substitution modalities: proposed methods for the evaluation of equivalence, traceability and pharmacovigilance reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-014-0483-Y

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

21 January 2018

1 reference

12 December 2020

WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007

1 reference

12 December 2020

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S11926-014-0483-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1003101135

0 references

1 reference